Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Assets: 2019-2024

Historic Current Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $303.4 million.

  • Allogene Therapeutics' Current Assets fell 14.35% to $260.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.7 million, marking a year-over-year decrease of 14.35%. This contributed to the annual value of $303.4 million for FY2024, which is 33.92% down from last year.
  • According to the latest figures from FY2024, Allogene Therapeutics' Current Assets is $303.4 million, which was down 33.92% from $459.1 million recorded in FY2023.
  • Allogene Therapeutics' Current Assets' 5-year high stood at $845.1 million during FY2020, with a 5-year trough of $303.4 million in FY2024.
  • In the last 3 years, Allogene Therapeutics' Current Assets had a median value of $459.1 million in 2023 and averaged $430.4 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Current Assets skyrocketed by 55.19% in 2020, and later slumped by 44.23% in 2021.
  • Over the past 5 years, Allogene Therapeutics' Current Assets (Yearly) stood at $845.1 million in 2020, then tumbled by 44.23% to $471.3 million in 2021, then grew by 12.20% to $528.8 million in 2022, then decreased by 13.18% to $459.1 million in 2023, then slumped by 33.92% to $303.4 million in 2024.